- ￥5334
- ebiosciences
- 15.6-1,000 pg/mL
- BMS2021INST
- 美国
- 2025年08月03日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 适应物种：
Human
- 检测范围：
15.6-1,000 pg/mL
- 检测方法：
ELISA
- 应用：
15.6-1,000 pg/mL
- 标记物：
人骨保护素OPG ELISA KIT
- 样本：
{Plasma=50 µL, Serum=50 µL, Supernatant=50 µL}
- 供应商：
Osteoprotegerin (TNFRSF11B) Human Instant ELISA™ Kit
- 库存：
128 Tests
- 规格：
盒
| Reactivity | Human |
|---|---|
| Sample Volume | 50 uL |
| Suitable Sample Types | cell culture supernatant, serum, plasma (EDTA, citrate, heparin) |
| Sensitivity | 2.5 pg/mL |
| Standard Curve Range | 15.6 - 1,000 pg/mL |
| Components | Aluminium pouch(es) with a Microwell Plate coated with Polyclonal Antibody to OPG, Biotin-Conjugate (anti-OPG polyclonal antibody), Streptavidin-HRP and Sample Diluent, lyophilized Aluminium pouch(es) with a human Osteoprotegerin Standard curve (coloured) Wash Buffer Concentrate 20x (phosphate-buffered saline with 1% Tween 20) Substrate Solution (tetramethyl-benzidine) Sample Diluent (Use when an external predilution of the samples is needed) Stop Solution (1M Phosphoric acid) Adhesive Plate Covers |
| Reported Applications | ELISA |
-
Citations: Pineda,B.; Laporta,P.; Cano,A.; Garcia-Perez,M.A.. The Asn19Lys substitution in the osteoclast inhibitory lectin (OCIL) gene is associated with a reduction of bone mineral density in postmenopausal women. Calcif.Tissue Int. 2008;82:348-353. (Link)
Boanini,Elisa; Torricelli,Paola; Gazzano,Massimo; Giardino,Roberto; Bigi,Adriana. Alendronate-hydroxyapatite nanocomposites and their interaction with osteoclasts and osteoblast-like cells. Biomaterials 2008;29:790-796(Link)
Capuccini,C.; Torricelli,P.; Sima,F.; Boanini,E.; Ristoscu,C.; Bracci,B.; Socol,G.; Fini,M.; Mihailescu,I.N.; Bigi,A.. Strontium-substituted hydroxyapatite coatings synthesized by pulsed-laser deposition: In vitro osteoblast and osteoclast response. Acta Biomaterialia 2008;4:1885-1893. (Link)
Breitkreutz,I.; Raab,M.; Vallet,S.; Hideshima,T.; Raje,N.; Mitsiades,C.; Chauhan,D.; Okawa,Y.; Munshi,N.; Richardson,P.; Anderson,K.. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 2008;22:1925-1932. (Link)
ELEFTHERIADIS,T.H.E.O.; ANTONIADI,G.E.O.R.; LIAKOPOULOS,V.A.S.S.; GALAKTIDOU,G.R.A.M.. The Effect of Paricalcitol on Osteoprotegerin Production by Human Peripheral Blood Mononuclear Cells. The Journal of Rheumatology 2009;36:856(Link)References: Blair,H.C.; Athanasou,N.A.. Recent advances in osteoclast biology and pathological bone resorption. Histol.Histopathol. 2004;19:189-199. (Link)
Sattler,A.M.; Schoppet,M.; Schaefer,J.R.; Hofbauer,L.C.. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. Calcif.Tissue Int. 2004;74:103-106. (Link)
Bengtsson,A.K.; Ryan,E.J.. Immune function of the decoy receptor osteoprotegerin. Crit Rev.Immunol. 2002;22:201-215. (Link)
Hofbauer,L.C.; Schoppet,M.. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004;292:490-495. (Link)
Roux,S.; Mariette,X.. The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-kappaB) and RANK Ligand expression. Leuk.Lymphoma 2004;45:1111-1118. (Link)
Aubin,J.E.; Bonnelye,E.. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption 7. Osteoporos.Int. 2000;11:905-913. (Link)
Cheng,X.; Kinosaki,M.; Murali,R.; Greene,M.I.. The TNF receptor superfamily: role in immune inflammation and bone formation. Immunol.Res. 2003;27:287-294. (Link)
Garnero,P.; Delmas,P.D.. Noninvasive techniques for assessing skeletal changes in inflammatory arthritis: bone biomarkers. Curr.Opin.Rheumatol. 2004;16:428-434. (Link)
Salmon,P.. Loss of chaotic trabecular structure in OPG-deficient juvenile Paget's disease patients indicates a chaogenic role for OPG in nonlinear pattern formation of trabecular bone. J.Bone Miner.Res. 2004;19:695-702. (Link)
Takahashi,N.; Udagawa,N.; Suda,T.. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem.Biophys.Res.Commun. 1999;256:449-455. (Link)
Schoppet,M.; Preissner,K.T.; Hofbauer,L.C.. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler.Thromb.Vasc.Biol. 2002;22:549-553. (Link)
Kostenuik,P.J.; Shalhoub,V.. Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. Curr.Pharm.Des 2001;7:613-635. (Link)
Wittrant,Y.; Theoleyre,S.; Chipoy,C.; Padrines,M.; Blanchard,F.; Heymann,D.; Redini,F.. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim.Biophys.Acta 2004;1704:49-57. (Link)
Saidenberg,Kermanac'h N.; Bessis,N.; Cohen-Solal,M.; De Vernejoul,M.C.; Boissier,M.C.. Osteoprotegerin and inflammation. Eur.Cytokine Netw. 2002;13:144-153. (Link)
Sezer,O.; Heider,U.; Zavrski,I.; Kuhne,C.A.; Hofbauer,L.C.. RANK ligand and osteoprotegerin in myeloma bone disease. Blood 2003;101:2094-2098. (Link)
Barille-Nion,S.; Bataille,R.. New insights in myeloma-induced osteolysis. Leuk.Lymphoma 2003;44:1463-1467. (Link)
Khosla,S.. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001;142:5050-5055. (Link)
Schett,G.; Redlich,K.; Smolen,J.S.. The role of osteoprotegerin in arthritis. Arthritis Res.Ther. 2003;5:239-245. (Link)
Saidenberg-Kermanac'h,N.; Cohen-Solal,M.; Bessis,N.; De Vernejoul,M.C.; Boissier,M.C.. Role for osteoprotegerin in rheumatoid inflammation. Joint Bone Spine 2004;71:9-13. (Link)
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验人 骨保护素（OPG ） 酶联免疫分析（ELISA ） 试剂盒使用说明书 本试剂仅供研究使用 目的：本试剂盒用于测定人血清，血浆及相关液体样本中 骨保护素（OPG ） 的 含量。 实验原理： 本试剂盒应用双抗体夹心法测定标本中人 骨保护素（OPG ） 水平。用纯化的人 骨保护素（OPG ） 抗体包被微孔板，制成固相抗体，往包被单抗的微孔中依次加入人 骨保护素（OPG ） ，再与 HRP 标记的 骨保护素（OPG
上海西唐生物科技有限公司 021-55229872, 65333639 www.westang.com 人骨保护素 ( OPG )ELISA 试剂盒 原理 本实验采用双抗体夹心 ABC-ELISA 法。用抗人 OPG 单抗包被于酶标板上，标准品和样品中的 OPG与单抗结合，加入生物素化的抗人 OPG ，形成免疫复合物连接在板上，辣根过氧化物酶标记的 Streptavidin 与生物素结合
上海西唐生物科技有限公司 021-55229872, 65333639 www.westang.com 兔骨保护素 ( OPG )ELISA 试剂盒 原理 本实验采用双抗体夹心 ABC-ELISA 法。用抗兔 OPG 单抗包被于酶标板上，标准品和样品中的 OPG与单抗结合，加入生物素化的抗兔 OPG ，形成免疫复合物连接在板上，辣根过氧化物酶标记的 Streptavidin
技术资料暂无技术资料 索取技术资料
